AngioDynamics

AngioDynamics Gross Profit

The Gross Profit of AngioDynamics (ANGO) as of Nov 4, 2026 is 174.89 M USD. In the previous year, Gross Profit was 157.71 M USD — a change of 10.90% (higher).

Gross Profit

174.89 MUSD

YoY

10.90%

Last updated:

Gross Profit of AngioDynamics is 2026 174.89 M USD. Gross Profit of AngioDynamics was 2025 157.71 M USD. It decreases by 10.90% higher compared to the previous year.

The AngioDynamics Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit
Date
Gross Profit
Jan 1, 2019
156.00 M USD
Jan 1, 2020
150.27 M USD
Jan 1, 2021
156.79 M USD
Jan 1, 2022
165.73 M USD
Jan 1, 2023
174.25 M USD
Jan 1, 2024
154.70 M USD
Jan 1, 2025
157.71 M USD
Jan 1, 2026
174.89 M USD
The AngioDynamics Gross Profit history
YEARGross ProfitYoY
174.89 MUSD+10.90%
157.71 MUSD+1.94%
154.70 MUSD-11.22%
174.25 MUSD+5.14%
165.73 MUSD+5.70%
156.79 MUSD+4.34%
150.27 MUSD-3.67%
156.00 MUSD+8.44%
143.86 MUSD-0.07%
143.95 MUSD-17.42%
174.32 MUSD-0.84%
175.80 MUSD-2.43%
180.17 MUSD+6.92%
168.51 MUSD+34.48%
125.31 MUSD-0.31%
125.70 MUSD-1.00%
126.97 MUSD+5.75%
120.07 MUSD+17.04%
102.59 MUSD+55.04%
66.17 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AngioDynamics Revenue

AngioDynamics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
303.91 M USD
-192.44 M USD
-184.35 M USD
Jan 1, 2025
292.50 M USD
-39.95 M USD
-33.99 M USD
Jan 1, 2026
320.17 M USD
-39.93 M USD
-36.74 M USD
Jan 1, 2027 (e)
337.93 M USD
-11.52 M USD
-11.26 M USD
Jan 1, 2028 (e)
355.37 M USD
-4.26 M USD
-4.33 M USD
Jan 1, 2029 (e)
375.40 M USD
12.50 M USD
9.07 M USD
Jan 1, 2030 (e)
397.40 M USD
19.55 M USD
15.25 M USD
Jan 1, 2031 (e)
419.60 M USD
22.18 M USD
17.31 M USD

AngioDynamics Margins

AngioDynamics stock margins

The AngioDynamics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AngioDynamics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AngioDynamics.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
50.90 %
-63.32 %
-60.66 %
Jan 1, 2025
53.92 %
-13.66 %
-11.62 %
Jan 1, 2026
54.62 %
-12.47 %
-11.48 %
Jan 1, 2027 (e)
54.62 %
-3.41 %
-3.33 %
Jan 1, 2028 (e)
54.62 %
-1.20 %
-1.22 %
Jan 1, 2029 (e)
54.62 %
3.33 %
2.42 %
Jan 1, 2030 (e)
54.62 %
4.92 %
3.84 %
Jan 1, 2031 (e)
54.62 %
5.29 %
4.13 %

AngioDynamics Stock analysis

What does AngioDynamics do? AngioDynamics Inc is a leading provider of medical devices and solutions for the treatment of vascular diseases and cancer. The company was founded in 1988 and is headquartered in Latham, New York. Over the years, AngioDynamics has evolved into a conglomerate through several acquisitions and partnerships, specializing in various areas. The key divisions include Vascular Access Solutions, Oncology Solutions, and Peripheral Vascular Solutions. AngioDynamics focuses on developing and manufacturing innovative technologies that improve medical care and promote patient health. The company develops and distributes a wide range of medical devices and procedures to treat diseases such as cancer, venous diseases, and thrombosis. In the Vascular Access Solutions division, AngioDynamics offers a wide range of devices for establishing vascular access, which are necessary for the treatment of serious illnesses. This includes port systems and catheters that facilitate access to the body's vascular system. AngioDynamics' Oncology Solutions provide targeted cancer treatment options, including ultrasound-controlled radiofrequency ablation systems and fusion biopsy systems. The development of innovative diagnostic and treatment options is a focus of AngioDynamics. A majority of AngioDynamics' products are in the Peripheral Vascular Solutions division. Here, the company develops devices and procedures for the treatment of peripheral vascular diseases such as varicose veins or chronic venous insufficiency. This includes procedures like laser and radiofrequency treatments that can be performed minimally invasively. AngioDynamics has gained an excellent reputation in the medical industry due to its high-quality products, innovative technologies, and close collaboration with medical professionals. The company places great emphasis on providing optimal care to every patient and therefore serves hospitals, clinics, and medical practices worldwide. Over the years, AngioDynamics has become a leading provider of medical devices and solutions for the treatment of vascular diseases and cancer. The company has built a broad customer base worldwide and has become an important player in the medical industry due to the quality and innovation of its products. AngioDynamics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AngioDynamics stock

Gross Profit of AngioDynamics is 174.89 M USD in 2026.

Gross Profit of AngioDynamics changed from 157.71 M USD to 174.89 M USD, representing a 10.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit AngioDynamics since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's AngioDynamics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — AngioDynamics

All Key Metrics — AngioDynamics